 |
20 Diseases |  |
29 Trials |
|
29 Trials |  |
1253 News |  |
| «12345678910111213...1920» |
- Zepatier (grazoprevir/elbasvir) / Merck (MSD), Daklinza (daclatasvir) / BMS, Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta Pharma
Eliminating hepatitis C virus infection in prisons: 7 years of experience (Poster Area) - May 12, 2022 - Abstract #EASLILC2022EASL_ILC_1941;
All the 79 patients were initially treated with Sofosbuvir/Ledipasvir and Daclatasvir with or without ribavirin (according to criteria defined in initial protocols) and more recently, Grazoprevir/Elbasvir and pangenotypic drugs, namely Sofosbuvir/Velpatasvir, and Glecaprevir/Pibrentasvir. Our encouraging data is a result from an optimized partnership between the healthcare team in prisons and our hospital, allowing a fast diagnosis, an agile disease staging and adequate treatment, minimizing future risk of transmission and taking us closer to eliminating the infection by 2030.
- Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta Pharma
Clinical impact of drug interaction in the use of antipsychotics by HCV patients treated with pangenotypic direct-acting antivirals (Poster Area) - May 12, 2022 - Abstract #EASLILC2022EASL_ILC_1858;
Potential DDIs between concomitant medication and the DAAs, Sofosbuvir/Velpatasvir [SOF/VEL] and Glecaprevir/Pibrentasvir [GLE/PIB], were evaluated using the University of Liverpool Hepatitis Interactions database...Two AE were reported with GLE/ PIB for quetiapine and paliperidone, and none with SOF/VEL... This analysis confirms that the greater use of SOF/VEL in patients with antipsychotic treatment may be due to its favorable DDI profile, which implies a lower number of adverse effects and required clinical actions.
- sofosbuvir/velpatasvir / Generic mfg.
A model to eradicate HCV in undocumented migrants and low-income refugees in Italy (Poster Area) - May 12, 2022 - Abstract #EASLILC2022EASL_ILC_1793;
The HCV RNApositive subjects have been treated with sofosbuvir-velpatasvir for 12 weeks and followed for 12 months from the end of therapy... This model seems to be effective to eradicate HCV infection among a difficult-to-manage population, such as undocumented migrants and low-income refugees
- | sofosbuvir/velpatasvir / Generic mfg.
Retrospective data, Journal: Impact of Proton Pump Inhibitors on Sustained Virologic Response in Veterans Treated with Sofosbuvir/Velpatasvir for chronic hepatitis C virus: a retrospective cohort study. (Pubmed Central) - May 10, 2022
Concomitant PPI treatment adjusted for other variables did not significantly impact success or failure of SOF/VEL treatment of chronic HCV. Despite the lack of significant association identified in this study, in efforts to provide the best care possible, it remains prudent to proceed with caution in patients desiring to use PPI therapy while receiving SOF/VEL, and ensure prescribing instructions are closely followed in regard to concomitant PPI use, especially in patients with other risk factors for decreased SVR.
- || Zepatier (grazoprevir/elbasvir) / Merck (MSD)
Clinical, Journal, Real-world evidence: Geographic Distribution of HCV Genotypes and Efficacy of Direct-Acting Antivirals in Chronic HCV-Infected Patients in North and Northeast China: A Real-World Multicenter Study. (Pubmed Central) - May 10, 2022
Genotypes 1b and 2a were dominant subtypes in North and Northeast China. The approved drug regimens EBR/GZR and SOF/LDV for subtype 1b and SOF/VEL for nongenotype 1b are the optimal effective and safety profile.
- | sofosbuvir/velpatasvir / Generic mfg., ledipasvir/sofosbuvir / Generic mfg.
Journal, HEOR: Cost-Effectiveness Analysis of Pan-Genotypic Sofosbuvir-Based Regimens for Treatment of Chronic Hepatitis C Genotype 1 Infection in China. (Pubmed Central) - Apr 28, 2022
SOF/LDV was found to be the most cost-effective treatment, and SOF/VEL was also economically dominant to pegIFN + RBV. These findings indicated that replacing pegIFN + RBV with DAA regimens could be a promising strategy.
- Zepatier (grazoprevir/elbasvir) / Merck (MSD), Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta Pharma
RETROSPECTIVE COHORT ANALYSIS OF FACTORS LINKED TO DIAGNOSTICS AND TREATMENT OF HEPATITIS C IN LARGE SAFETY NET HOSPITAL IN LOS ANGELES (6F - San Diego Convention Center) - Apr 25, 2022 - Abstract #DDW2022DDW_2163;
Targeting education to those with gaps in the cascade of care are needed. The decline of testing and treatment between 2020-2021 was secondary to the COVID 19 pandemic, highlighting potential exacerbation of difficulties of care coordination in hepatitis C management.
- sofosbuvir/velpatasvir / Generic mfg.
EFFICACY AND SAFETY OF PAN-GENOTYPIC SOFOSBUVIR AND VELPATASVIR IN PATIENTS WITH HEPATITIS C REINFECTION FOLLOWING ATTAINMENT OF SUSTAINED VIROLOGICAL RESPONSE WITH NS5A INHIBITORS (Poster Hall - San Diego Convention Center) - Apr 25, 2022 - Abstract #DDW2022DDW_951;
No grade III/IV adverse events were observed. Conclusion :Treatment with the pan-genotypic combination of Sofosbuvir and Velpatasvir is highly effective and safe in patients with HCV reinfection.
- Tivicay (dolutegravir) / ViiV Healthcare
EFFICACY AND SAFETY OF PAN-GENOTYPIC SOFOSBUVIR AND VELPATASVIR IN PATIENTS WITH CHRONIC HEPATITIS C AND HIV CO-INFECTION ON DOLUTEGRAVIR BASED ANTI-RETROVIRAL THERAPY (Poster Hall - San Diego Convention Center) - Apr 25, 2022 - Abstract #DDW2022DDW_950;
No grade III/IV adverse events were reported and there was no worsening of hemogram, liver or renal function test parameters during treatment. Conclusion :The pan-genotypic regimen of S+V is safe and effective in PLHA with HCV co-infection who are on TLD.
- Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta Pharma
LESSONS FROM HEPATITIS C TREATMENT DURING THE COVID-19 PANDEMIC: DECREASED RESOURCE UTILIZATION LEADS TO SIMILAR EFFICACY IN BRITISH COLUMBIA, CANADA (Poster Hall - San Diego Convention Center) - Apr 25, 2022 - Abstract #DDW2022DDW_946;
Conclusion : The COVID-19 pandemic has led to a decrease in HCV treatment rates. However, treatment completion and SVR rates remained high among those treated, suggesting minimal-pre-treatment investigations and use of telemedicine can optimize scarce resources with similar efficacy.
- ribavirin / Generic mfg., sofosbuvir/velpatasvir / Generic mfg.
EFFICACY AND SAFETY OF ADDING RIBAVIRIN FOR GENOTYPE 3 HCV COMPENSATED CIRRHOSIS RECEIVING 12-WEEKS OF SOFOSBUVIR/VELPATASVIR: A META-ANALYSIS (ePoster - DDW Virtual) - Apr 25, 2022 - Abstract #DDW2022DDW_893;
Conclusion : In GT3 compensated cirrhosis patients treated with 12 weeks of SOF/VEL, RBV was associated with higher adverse events without significant improvement in SVR12. Our findings suggest routine RBV is not mandatory for GT3 compensated cirrhosis patients treated with SOF/VEL.
- || sofosbuvir/velpatasvir / Generic mfg.
Clinical, P4 data, Journal: A minimal monitoring approach for the treatment of hepatitis C virus infection (ACTG A5360 [MINMON]): a phase 4, open-label, single-arm trial. (Pubmed Central) - Apr 21, 2022
P4
In this diverse global population of people with HCV, the MINMON approach with sofosbuvir-velpatasvir treatment was safe and achieved SVR comparable to standard monitoring observed in real-world data. Coupled with innovative case finding strategies, this strategy could be crucial to the global HCV elimination agenda.
- | Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta Pharma, NATDAC (daclatasvir) / NATCO, Hetero, Vemlidy (tenofovir alafenamide) / Gilead
Journal, Real-world evidence: Real-world effectiveness of direct-acting antivirals in people living with human immunodeficiency virus and hepatitis C virus genotype 6 infections. (Pubmed Central) - Apr 19, 2022
Coupled with innovative case finding strategies, this strategy could be crucial to the global HCV elimination agenda. Similar to the observation made in HIV-negative patients, sustained virologic response 12 wk off-therapy with DAAs is high in PLWH coinfected with HCV-6.
- | sofosbuvir/velpatasvir / Generic mfg.
Journal: Efficacy and safety of the sofosbuvir/velpatasvir combination for the treatment of patients with early mild to moderate COVID-19. (Pubmed Central) - Apr 14, 2022
No significant side effects were observed in the SOF/VEL group. Early SOF/VEL treatment in mild/moderate COVID-19 seems to be safe and effective for faster elimination of SARS-CoV-2 and to prevent disease progression.
- | Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta Pharma, Sovaldi (sofosbuvir) / Gilead
Trial completion date, Trial primary completion date: SCALE-C: Strategies for Hepatitis C Testing and Treatment in Aboriginal Communities That Lead to Elimination (clinicaltrials.gov) - Apr 14, 2022
P=N/A, N=600, Recruiting, Sponsor: Kirby Institute
Early SOF/VEL treatment in mild/moderate COVID-19 seems to be safe and effective for faster elimination of SARS-CoV-2 and to prevent disease progression. Trial completion date: Feb 2022 --> Aug 2022 | Trial primary completion date: Feb 2022 --> Aug 2022
- | Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta Pharma
Journal, Real-world evidence: Pan-Genotypic Direct-Acting Antiviral Agents for Undetermined or Mixed-Genotype Hepatitis C Infection: A Real-World Multi-Center Effectiveness Analysis. (Pubmed Central) - Apr 13, 2022
Laboratory adverse events with grades ≥3 included anemia (2.5%), thrombocytopenia (2.5%), and jaundice (0.7%). Pan-genotypic DAAs are effective and well-tolerated for mixed-genotype or genotype-undetermined HCV infection real-world settings.
- ||| sofosbuvir/velpatasvir / Generic mfg.
Enrollment open: STORC: Sofosbuvir/Velpatasvir Treatment of Chronic Hepatitis C During Pregnancy (clinicaltrials.gov) - Apr 12, 2022
P4, N=100, Recruiting, Sponsor: Catherine Chappell
Pan-genotypic DAAs are effective and well-tolerated for mixed-genotype or genotype-undetermined HCV infection real-world settings. Not yet recruiting --> Recruiting
- || Zepatier (grazoprevir/elbasvir) / Merck (MSD), Daklinza (daclatasvir) / BMS
Clinical, Journal, Real-world evidence: Real-world efficacy and safety of direct-acting antiviral drugs in patients with chronic hepatitis C and inherited blood disorders. (Pubmed Central) - Apr 12, 2022
DAA-based regimens are well tolerated and highly efficacious in patients with chronic hepatitis C and IBLD in the real-world setting. Thus, DAA-based antiviral treatment should be prioritized in this thus far neglected population of HCV-infected patients.
- | Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta Pharma
Trial termination, Trial primary completion date: Pan-genotypic Direct Acting Antiviral Therapy in Donor HCV-positive to Recipient HCV-negative Lung Transplant (clinicaltrials.gov) - Apr 11, 2022
P4, N=21, Terminated, Sponsor: Massachusetts General Hospital
Thus, DAA-based antiviral treatment should be prioritized in this thus far neglected population of HCV-infected patients. Enrolling by invitation --> Terminated | Trial primary completion date: Dec 2021 --> Apr 2022; Lack of funding, transitioned to standard of care
- | sofosbuvir/velpatasvir / Generic mfg.
Trial completion date: STORC: Sofosbuvir/Velpatasvir Treatment of Chronic Hepatitis C During Pregnancy (clinicaltrials.gov) - Apr 4, 2022
P4, N=100, Not yet recruiting, Sponsor: Catherine Chappell
Enrolling by invitation --> Terminated | Trial primary completion date: Dec 2021 --> Apr 2022; Lack of funding, transitioned to standard of care Trial completion date: Dec 2024 --> Apr 2025
- || ribavirin / Generic mfg.
Clinical, Journal: The use of antiviral drugs in children. (Pubmed Central) - Mar 25, 2022
Some drugs are used to treat congenital infections, such as valganciclovir and ganciclovir in congenital cytomegalovirus infection...Treatment with direct antiviral agents against hepatitis C virus is approved for children over the age of three; it consists in different therapeutic regimens chosen on the basis of the viral genotype (ledipasvir/sofosbuvir for genotypes 1, 4, 5 and 6, sofosbuvir/ribavirin for genotypes 2 and 3, sofosbuvir/velpatasvir and glecaprevir/pibrentasvir for all genotypes) and it has dramatically changed the course of the illness. Many molecules have been studied in order to treat SARS-CoV-2 infection, but only remdesivir seems to play a role in shortening recovery time, although inclusion criteria are very specific and data on the use in children is limited.
- Vosevi (sofosbuvir/velpatasvir/voxilaprevir) / Gilead, Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta Pharma
SIMPLIFICATION OF CARE FOR HCV IS EFFECTIVE DURING THE COVID PANDEMIC: A RETROSPECTIVE STUDY OF HCV TREATMENT UTILIZING THE BRITISH COLUMBIA HEPATITIS C NETWORK ([VIRTUAL]) - Mar 25, 2022 - Abstract #CDDW2022CDDW_214;
There was slightly less use of sofosbuvir/velpatasvir/voxilaprevir at (2% vs 4% pre-pandemic).The proportion of patients who completed lab work for SVR was similar during the pandemic (n=83/97, 85.6%) compared to pre-pandemic (n=120/143, 83.9%)...Conclusions Less persons were treated during the COVID pandemic, which may deter progress towards HCV elimination targets. Very high SVR12 and treatment completion rates during the pandemic suggest that patients can be effectively treated with less pre-treatment investigations and fewer appointments.
- | ribavirin / Generic mfg., sofosbuvir/velpatasvir / Generic mfg.
Journal: The Novel Finding of Dynamic Change in eGFR Up to One Year after End of Treatment in HCV-Infected Patients Receiving Sofosbuvir and Velpatasvir. (Pubmed Central) - Mar 17, 2022
The close monitoring of renal function is warranted. Further study should be conducted in order to weigh the risks and benefit of RBV.
- Vosevi (sofosbuvir/velpatasvir/voxilaprevir) / Gilead
Early post liver transplant rescue treatment with sofosbuvir/velpatasvir/voxilaprevir in patients experienced to NS5A-inhibitors (Poster Area) - Mar 16, 2022 - Abstract #EASLILC2022EASL_ILC_1488;
One pt developed cholestatic hepatitis which reverted after prompt interruption of tx. Early post-LT DAA tx prevented liver damage by HCV and allowed the use of suboptimal grafts (old donor, HCV viremic donor or with moderate macrovesicular steatosis).
- Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta Pharma
High efficacy and safety of pan-genotypic direct-acting antiviral regimens in adolescents and children: a global systematic review to inform new World Health Organization recommendations (Poster Area) - Mar 16, 2022 - Abstract #EASLILC2022EASL_ILC_1413;
There is currently no direct evidence for SOF/DCV in young children, and studies are planned for 2022. SOF/DCV remains the most affordable and available DAA regimen for adults globally, and alignment of adult and paediatric procurement would simplify supply chain management.
- sofosbuvir/velpatasvir / Generic mfg.
Sofosbuvir/Velpatasvir (S/V) for the treatment of HCV infection among vulnerable inner-city residents: extending the results of clinical trial (Poster Area) - Mar 16, 2022 - Abstract #EASLILC2022EASL_ILC_1412;
Through dedicated initiatives, it is possible to identify vulnerable inner-city residents whowere previously diagnosed with HCV infection and had never been offered treatment for it. These initiatives, combined with dedicated programs to provide HCV treatment in an optimized manner, must be considered to achieve HCV elimination in this unique population.
- sofosbuvir/velpatasvir / Generic mfg., ledipasvir/sofosbuvir / Generic mfg.
Treatment of hepatitis C in primary healthcare in the country of Georgia (Meeting Point 1) - Mar 16, 2022 - Abstract #EASLILC2022EASL_ILC_1409;
Our study reported the effectiveness of a simplified HCV treatment model in PHCs. Expanding this integrated decentralized model of HCV treatment nationwide would provide an opportunity to improve linkage to care and close gaps in the HCV cascade of care.
- Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta Pharma
Use of comedication in patients with hepatitis C and addiction or drug abuse treated with direc-acting antivirals: implication in drug-drug interactions (Poster Area) - Mar 16, 2022 - Abstract #EASLILC2022EASL_ILC_1403;
Possible DDIs with direct-acting antivirals (DAAs) (Sofosbuvir/Velpatasvir [SOF/VEL] and Glecaprevir/Pibrentasvir [GLE/PIB]) were evaluated using the University of Liverpool Interactions for Hepatitis database. In Spain, 9% of HCV patients with addictions to substance or drug abuse taking ≥2 comedications are at risk of multi-DDIs.
- Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta Pharma
Polypharmacy and prevalence of multi drug-drug interactions in hepatitis C patients treated with pangenotypic direct acting antivirals: an analysis from three european countries (Meeting Point 1) - Mar 16, 2022 - Abstract #EASLILC2022EASL_ILC_1402;
Across Germany, Italy, and Spain, 8.9% of HCV patients taking medications concomitantly during their pDAA therapy are at risk of multiple DDIs. Accurate prediction of the impact of multiple DDIs on pDAA efficacy and safety is difficult; this should prompt a thorough pDDI assessment before HCV therapy in comorbid patients.
- sofosbuvir/velpatasvir / Generic mfg.
Real-life effectiveness and safety of sofosbuvir/velpatasvir in difficult to treat hepatitis C patients (Poster Area) - Mar 16, 2022 - Abstract #EASLILC2022EASL_ILC_1401;
70.3% have failed prior DAA treatment (Daclatasvir + asunaprevir n = 16, sofosbuvir+ribavirin n = 3, sofosbuvir + ledipasvir n = 2, glencaprevir+ pibrentasvir n = 3, boceprevir n = 1) Naïve patients received SOF/VEL for 12 weeks and the patientswith prior DAA failure received SOF/VEL for 24 weeks, ribavirin was added in 78.4% of treatment schedules. SOF/VEL is an effective and safe retreatment for difficult to treat HCV population in a real-life setting.
- Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta Pharma
Treating HCV in dual diagnosis acute psychiatric inpatients with substance use disorder (Poster Area) - Mar 16, 2022 - Abstract #EASLILC2022EASL_ILC_1396;
We present our ongoing experience of treating HCV in a population of drug dependent patients with SMI during their inhospital stay. This model has proved efficiency in facilitating their access to care and achieving SVR where no other approach proved successful.
- Sovaldi (sofosbuvir) / Gilead
Sofosbuvir plus velpatisvir for 8 weeks in patients with acute hepatitis C: multicenter, single arm, phase 2 study (The HepNet acute HCV-V study) (Poster Area) - Mar 16, 2022 - Abstract #EASLILC2022EASL_ILC_1394;
The 8-week treatment with SOF/VEL was well tolerated and highly effective in patients with acute HCV monoinfection. Early treatment of hepatitis C might effectively prevent the spread of HCV in high-risk groups and should therefore be more targeted; ideally, approval for hepatitis C therapy should be pursued independently of chronic hepatitis C.
- sofosbuvir/velpatasvir / Generic mfg.
Changing HCV patient profiles: insights from a large multinational real-world sofosbuvir/velpatasvir (SOF/VEL) dataset (Poster Area) - Mar 16, 2022 - Abstract #EASLILC2022EASL_ILC_1393;
Antipsychotic drug use appeared similar in males and females, despite significantly fewer mental health disorders in male pts. TT varied from 1 day to >6 months and was shorter in males.
- Requests for drug-drug interaction data on direct-acting antivirals and enzyme inducing anti-epileptic agents: an overview of the HEP Interaction checker database of the University of Liverpool (Poster Area) - Mar 16, 2022 - Abstract #EASLILC2022EASL_ILC_1392;
Our recommendations have recently been updated to reflect recent real-life data. Given the high numberof DDI requests involving an eiAE and DAAs, we believe physicians should be informed that treatment options have now been improved, and HCV treatment should no longer be deferred when an eiAE is on board.
- ribavirin / Generic mfg., sofosbuvir/velpatasvir / Generic mfg.
Is routine Ribavirin mandatory for genotype 3 hepatitis C compensated cirrhosis patients receiving Sofosbuvir/Velpatasvir? A meta-analysis (Poster Area) - Mar 16, 2022 - Abstract #EASLILC2022EASL_ILC_1369;
Ribavirin did not significantly increase the SVR12 in GT3 compensated cirrhosis patients receiving SOF/VEL. Our findings suggest limited role for RBV as routine add-on therapy to SOF/VEL in GT3 compensated cirrhosis patients.
- Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta Pharma
Treating children with HCV close to home through a virtual national multidisciplinary network (Poster Area) - Mar 16, 2022 - Abstract #EASLILC2022EASL_ILC_1345;
DAA therapy prescribed: Harvoni (21); Epclusa (11); Maviret (2). The National HCV pMDT ODN delivers high quality treatment & equity of access for children & young people, 3–18 yrs with HCV in England, ensuring they receive care close to home with 100% cure rates.
- Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta Pharma
Hepatitis C treatment during the COVID-19 pandemic has similar efficacy with less resource utilization: analysis from the British Columbia HCV network (Poster Area) - Mar 16, 2022 - Abstract #EASLILC2022EASL_ILC_1332;
Patients with HCV infection treated during the COVID-19 pandemic utilized significantly less resources, had a higher rate of treatment completion, and similar rate of SVR. Treatment simplification through the use of telemedicine, minimizing investigations, and leveraging fewer healthcare resources can maintain high treatment completion and SVR rates.
- sofosbuvir/velpatasvir / Generic mfg.
The health economic outcomes of trial ACTG5360/MINMON (Poster Area) - Mar 16, 2022 - Abstract #EASLILC2022EASL_ILC_1331;
ACTG A5360 (MINMON) was a 5 country, single arm study providing 12 weeks of sofosbuvir/velpatasvir to people with HCV infection with no planned visits prior to SVR evaluation (Week 24)... MINMON is likely a cost saving strategy compared to the SoC for HCV treatment.
- sofosbuvir/velpatasvir / Generic mfg.
A model, screen test and treat hepatitis C elimination project among under-served communities in Islamabad-the federal capital of Pakistan (Poster Area) - Mar 16, 2022 - Abstract #EASLILC2022EASL_ILC_1295;
Same day hepatitis C testing and treatment initiation is feasible among underserved communities in urban slums in Pakistan. CHWs can be effective in reaching “hard-to-reach” populations with limited access to health services and achieving high rates of linkage to care and adherence with treatment for hepatitis C.
- Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta Pharma
Global survey of healthcare workers' attitudes to treatment of chronic hepatitis C infection in children and adolescents (Poster Area) - Mar 16, 2022 - Abstract #EASLILC2022EASL_ILC_1270;
This survey demonstrates strong HCW support for treatment of children and adolescents with HCV infection, especially those 6 years or older. Future priorities include updating national policies to incorporate case-finding strategies and treatment for children and adolescents, and access to paediatric DAA formulations.
- Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta Pharma, Sovaldi (sofosbuvir) / Gilead
Glecaprevir/pibrentasvir and sofosbuvir for 16 weeks without ribavirin is safe and highly effective retreatment for patients who have failed an NS5A inhibitor containing antiviral regimen (Capital Suite 7) - Mar 16, 2022 - Abstract #EASLILC2022EASL_ILC_521;
Glecaprevir/pibrentasvir plus sofosbuvir for 16 weeks is a safe and highly effective retreatment regimen for patients who have previously failed GLE/PIB and other DAA regimens regardless or cirrhosis status, or NS5A RAS profile. There is no indication for adding ribavirin.
- | sofosbuvir/velpatasvir / Generic mfg.
Trial completion date, Trial primary completion date: Transplanting Hepatitis C Positive Organs (clinicaltrials.gov) - Mar 16, 2022
P4, N=100, Recruiting, Sponsor: Brigham and Women's Hospital
There is no indication for adding ribavirin. Trial completion date: Dec 2021 --> Dec 2023 | Trial primary completion date: Dec 2020 --> Dec 2023
- | sofosbuvir/velpatasvir / Generic mfg.
Enrollment open, Trial initiation date: Same-visit Hepatitis C Testing and Treatment (The QuickStart Study) (clinicaltrials.gov) - Mar 15, 2022
P4, N=1800, Recruiting, Sponsor: Macfarlane Burnet Institute for Medical Research and Public Health Ltd
Trial completion date: Dec 2021 --> Dec 2023 | Trial primary completion date: Dec 2020 --> Dec 2023 Not yet recruiting --> Recruiting | Initiation date: Oct 2021 --> Mar 2022
- | Vosevi (sofosbuvir/velpatasvir/voxilaprevir) / Gilead
Journal: Expanding the epidemiological understanding of hepatitis C in South Africa: Perspectives from a patient cohort in a rural town. (Pubmed Central) - Mar 10, 2022
The cohort was of older age with a significant number having advanced fibrosis or cirrhosis, suggesting HCV acquisition in the distant past. Using a simplified care approach, treatment outcomes were very good.
- sofosbuvir/velpatasvir / Generic mfg.
Evaluation of the clinical and economic value of sofosbuvir/velpatasvir (SOF/VEL) in patients with chronic hepatitis C in Spain during the last 5 years () - Mar 9, 2022 - Abstract #AEEH2022AEEH_70;
- || sofosbuvir/velpatasvir / Generic mfg.
Retrospective data, Review, Journal: Sofosbuvir plus velpatasvir combination for the treatment of chronic hepatitis C in patients with end stage renal disease on renal replacement therapy: a systematic review and meta-analysis. (Pubmed Central) - Mar 8, 2022
Using a simplified care approach, treatment outcomes were very good. The fixed-dose combination of SOF and VEL is effective and safe in CHC patients with ESRD on RRT.
- sofosbuvir/velpatasvir / Generic mfg.
Outcome Assessment of Sofosbuvir / Velpatasvir for the Treatment of Patients with Hepatitis C in Colombia (In-person & Virtual) - Mar 8, 2022 - Abstract #ISPOR2022ISPOR_1663;
Treatment with sofosbuvir/velpatasvir in patients with HCV Colombia and generates a saving of $ 20,816 per patient for Colombia's healthcare system. The benefit of treatment with sofosbuvir/velpatasvir is a reduction in liver transplants and a reduction in productivity.
- sofosbuvir/velpatasvir / Generic mfg., ledipasvir/sofosbuvir / Generic mfg.
Uptake and Utilization Trends of Direct-Acting Antivirals (DAA) for Hepatitis-C in Manitoba, Canada between 1999 and 2019 (In-person & Virtual) - Mar 8, 2022 - Abstract #ISPOR2022ISPOR_927;
CONCLUSIONS : After their introduction, a rapid uptake of newer DAAs was observed in Manitoba and by the end of 2019 DAAs had taken the entire market of HCV medications. Although uptake of DAAs in Manitoba was enthusiastic, efforts are needed to further increase DAA use in order to achieve the goal of HCV elimination.
- sofosbuvir/velpatasvir / Generic mfg.
Measuring the Real-World Impact of Subsidy Decision on Clinical Practice and Patient Outcomes: Post-Subsidy Evaluation of Sofosbuvir/Velpatasvir for Treating Chronic Hepatitis C () - Mar 8, 2022 - Abstract #ISPOR2022ISPOR_29;
The subsidy decision had led to increased accessibility to patients and intended changes in clinical practice. Sofosbuvir/velpatasvir was clinically effective and safe in the real-world, with a potential to bring about significant cost savings to the healthcare system by averting progression to liver complications and liver-related deaths.
- | ribavirin / Generic mfg.
Journal, HEOR: Cost-utility analysis of four WHO-recommended sofosbuvir-based regimens for the treatment of chronic hepatitis C in sub-Saharan Africa. (Pubmed Central) - Mar 8, 2022
Generic sofosbuvir/daclatasvir is very cost-effective for treating chronic hepatitis C in sub-Saharan Africa. Large-scale use of generics and an increase in national and international funding for hepatitis C treatment must be priorities for the HCV elimination agenda.